APA aipamena

Weng, X., Luo, S., Lin, S., Zhong, L., Li, M., Xin, R., . . . Xu, X. (2020). Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels. Oncol Res.

Chicago Style aipamena

Weng, Xiuhua, Shaohong Luo, Shen Lin, Lixian Zhong, Meiyue Li, Rao Xin, Pinfang Huang, and Xiongwei Xu. "Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy As First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels." Oncol Res 2020.

MLA aipamena

Weng, Xiuhua, et al. "Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy As First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels." Oncol Res 2020.